This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AAT (IH)

Kamada Ltd.

Drug Names(s): AAT, Inhaled Alpha 1-Antitrypsin

Description: BioMedTracker maintains separate drug profiles for the inhaled (IH) and intravenous (IV) formulations of Alpha 1-Antitrypsin (AAT).

AAT is a proprietary compound targeting the protease inhibitor A1AT.

Deal Structure: Kamada and Chiesi
In August 2012, Kamada announced it has entered into an exclusive distribution agreement with Chiesi for the distribution of its breakthrough inhaled alpha-1 antitrypsin for treatment of alpha-1 antitrypsin deficiency (AATD-IH). Under the terms of the agreement, Kamada will receive milestone payments of $60 million, subject to achievement of certain regulatory and sales targets. In addition, Chiesi is committed to minimum purchases tens of millions USD during the first 5 years following the acceptance of the required regulatory approvals. The agreement is for 12 years.

According to the agreement, Chiesi will be responsible for the distribution of Kamada's AATD-IH product in Europe, Turkey and former CIS countries including promoting the drug, identifying patients and handling reimbursements. Kamada retains all rights in its AAT-IV products or other AAT-IH indications products and it was agreed that both companies will examine additional...See full deal structure in Biomedtracker

Partners: Chiesi Farmaceutici S.p.A.


AAT (IH) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug